This week on The Beat, CTSNet Editor-in-Chief Joel Dunning reflects on the most popular content of 2025 on CTSNet. Chapters 00:00 Intro 02:15 Top Interview 03:52 Top Webinar 05:23 Top Clinical Video 06:24 Top JANS Article 07:01 Top Video Series 08:02 Top Contributor 08:59 Top Cardiac Procedures 12:14 Top Podcasts 17:02 JANS 1, Doctor Story 21:28 JANS 2, Ex Vivo Heart Perfusion 22:41 JANS 3, PCI vs CABG 24:04 JANS 4, NEOpredict-Lung 25:29 2026 Plans He discusses the top interview, the most popular webinar, and reveals the leading CTSNet contributor of the year. He also highlights the most-read JANS article, the most viewed CTSNet series, the top clinical videos in cardiac surgery, and the leading podcast episodes of 2025 from both The Beat and The Atrium. Additionally, he shares key statistics about CTSNet, including website viewership, YouTube subscribers, and listener demographics.   Joel also highlights recent JANS articles on if ex vivo heart perfusion offsets ischemic penalties with six-hour or greater preservation in adult donation after brain death heart transplantation, an impactful article titled “This Man Saved My Life—I Live by His Example,” the long-term outcomes for women with chronic coronary artery disease after percutaneous coronary intervention vs coronary artery bypass grafting, and the long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).    In addition, Joel outlines CTSNet’s goals and initiatives to look forward to in 2026. Before closing, he highlights upcoming events in CT surgery.    JANS Items Mentioned  1.)  Ex Vivo Heart Perfusion Offsets Ischemic Penalties With ≥6-Hour Preservation in Adult Donation-After-Brain-Death Heart Transplantation  2.) This Man Saved My Life—I Live by His Example  3.) Women With Chronic Coronary Artery Disease: Long-Term Outcomes After Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting  4.) Long-Term Outcomes of Preoperative Nivolumab With or Without Relatlimab in Patients With Resectable Non-Small-Cell Lung Cancer (NEOpredict-Lung)  CTSNet Content Mentioned  1.) CTSNet Summarized—Most Popular Content of 2025  2.) CTSNet Summarized—Most Popular Podcast Episodes of 2025  3.) CTSNet Summarized—Top Cardiac Procedure Videos of 2025   Other Items Mentioned  1.) All CTSNet Summarized Content   2.) 2025 CTSNet Recruitment Guide   3.) Career Center   4.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.